Citations

Clear

367 citation(s) found for "Benson, Al".

Real-world Effectiveness of Initial Treatment with Newer versus Injectable Disease-modifying Therapies in Pediatric Multiple Sclerosis (625)
Aaen, Gregory , Belman, Anita , Gorman, Mark , Harris, Yolanda, Lotze, Timothy , Mar, Soe , Moodley, Manikum , Ness, Jayne , Rodriguez, M Herrera, Rose, John , Schreiner, Teri , Tillema, Jan‐Mendelt , Waltz, Michael , Casper, T. Charles , Krysko, Kristen M. , Graves, Jennifer , Rensel, Mary R. , Weinstock‐Guttman, Bianca , Rutatangwa, Alice , Benson, Leslie , Chitnis, Tanuja , Goyal, Manu S. , Krupp, Lauren , Schreiner, Teri , Waubant, Emmanuelle L.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.625 Get It

Measuring Ambulatory Neurologic Health Disparities with the Axon Registry (P18-13.008)
Benish, Sarah E. , Esper, Gregory J. , Marulanda-Londoño, Erika, Hope, Omotola , Pham, Tammy , Roe, Matthew T. , Torres, Aracelis Z. , Lien, Amanda , Kauwe, Steven, Mante, Aristotle, Lundgren, Karen B. , Schierman, Becky, Benson, Richard , Benish, Sarah, Kissela, Brett , Rosendale, Nicole , Lien, Amanda, Jones, Lyell K.

Mayo Clinic

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.2919 Get It

Cauda equina neuroendocrine tumors: A single institutional imaging review of cases over two decades
Ajmera, Pranav , Mehta, P. , Benson, John C. , Madhavan, Ajay A. , Bathla, Girish , Agarwal, Amit K, Mehta, Parv M, Benson, John , Madhavan, Ajay A , Diehn, Felix E. , Soni, Neetu , Bathla, Girish , Ajmera, Pranav , Mehta, Parv , Agarwal, Amit

Mayo Clinic

The Neuroradiology Journal | November 7, 2023 | Volume: 37 | Issue: 1 | Pages: 84-91

10.1177/19714009231212359 | PMID 37933451 Get It

Cauda Equina Neuroendocrine Tumors (CE-NET), previously referred to as paragangliomas are a rare subset of spinal tumors, with limited data on imaging. Herein, we present a retrospective review of clinical and imaging findings of CE-NETs in ten patients who were evaluated at our institution over the past two decades. All patients had well-defined intradural lesions in the lumbar spine which demonstrated slow growth. A review of imaging findings revealed the presence of an eccentric vascular pedicle along the dorsal aspect of the tumor in 8 of the 10 patients (eccentric vessel sign), a distinctive finding that has not previously been reported with this tumor and may help improve the accuracy of imaging-based diagnosis. In all cases, a gross-total resection was performed, with resolution of symptoms in most of the cases.
Abstract 19141: Carotid Artery Plaque Rim Sign on Computed Tomography Angiography is Associated With Intraplaque Hemorrhage and Inflammatory Microenvironment
Nardi, Valentina , Rajotia, Arush , Saba, Luca , Lerman, Lilach O. , Nardi, Valentina , Benson, John C. , Saba, Luca , Lerman, Amir

Mayo Clinic

Circulation | November 6, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.19141 Get It

Introduction: The carotid artery rim sign on CTA is characterized by soft-plaque components surrounded by a rind of thin, adventitial calcification and its role in plaque instability is not established yet. Intraplaque hemorrhage (IPH) and the inflammatory microenvironment in carotid atheroma are considered features of atherosclerotic plaque vulnerability leading to cerebrovascular events. Hypothesis: The association between rim sign on CTA and carotid IPH and inflammation remains scantly investigated. In this study, we aimed to determine whether rim sign is associated with IPH on MRA and with the extent of IPH and inflammation on histology. We hypothesized that rim sign may be a radiological predictor of carotid IPH and inflammation. Methods: We retrospectively enrolled 100 consecutive patients who underwent carotid endarterectomy (CEA) and neck CTA before CEA. On CTA, the ipsilateral rim sign was defined as the presence of adventitial calcifications with internal soft-tissue plaque of ≥2 mm in maximum thickness. Of the included patients, 25 had MRA with 3D magnetization-prepared rapid acquisition with gradient echo (MPRAGE) sequence. Carotid plaque specimens were collected and stained with H&E to quantify IPH (%). Histologically, we defined IPH as an area of carotid plaque with blood elements, and inflammatory microenvironment as the presence of lymphocytes and plasma cells (chronic inflammation) and foam cells. Results: The rim sign on CTA was present in 56 (56%) of patients. IPH on MRA was present in 11 (44%) patients. The rim sign was significantly associated with the presence of IPH on MRA [9 (81.8%) vs 2 (14.3%); p=0.003]. On histology, the rim sign was associated with a higher extent of IPH [5.0 % (IQR 2.0-25.0) vs 5.0% (IQR 0.0-10.0); p=0.017], with chronic inflammation [44 (78.6%) vs 12 (21.4%); p=0.003], and foam cells [51 (91.1%) vs 5 (8.9%); p<0.001]. Conclusions: These findings suggest that rim sign on CTA may be proposed as a potential imaging marker of IPH as well as a histologic predictor of IPH extent and carotid plaque inflammatory microenvironment.
Clinical and imaging outcomes of 100 patients with cerebrospinal fluid-venous fistulas treated by transvenous embolization
Brinjikji, Waleed , Garza, Ivan , Whealy, Mark , Mark, Ian T. , Morris, Pearse , Verdoorn, Jared T. , Benson, John C. , Atkinson, John L. D., Cutsforth‐Gregory, Jeremy K. , Madhavan, Ajay, Mark, Ian , Morris, Pearse P, Verdoorn, Jared T , Benson, John , Kobeissi, Hassan , Cutsforth-Gregory, Jeremy K , Madhavan, Ajay A. , Kissoon, Narayan , Kobeissi, Hassan

Mayo Clinic

Journal of NeuroInterventional Surgery | October 28, 2023 | Volume: 16 | Issue: 12 | Pages: 1256-1263

10.1136/jnis-2023-021012 | PMID 37898553 Get It

Background Cerebrospinal fluid-venous fistulas (CSFVF) are a common cause of spontaneous intracranial hypotension (SIH). Transvenous embolization has emerged as a reliable treatment option. We review the clinical presentation, imaging, and clinical outcomes of 100 consecutive CSFVF patients who underwent embolization over 2 years. Methods Baseline clinical characteristics, imaging findings (including Bern SIH score), technical outcomes, and long-term imaging and clinical outcomes were collected. All patients had at least 3 months of clinical follow-up and had baseline MRI. 99/100 patients underwent follow-up imaging at ≥3 months post-treatment. Results 100 patients were included. Mean imaging and clinical follow-up duration was 8.3±7.7 months and 15.0±6.8 months, respectively. The mean duration of symptoms before embolization was 40.9±52 months. Mean baseline Bern SIH score was 5.9±3.3. The most common baseline symptoms were headache (96 patients), tinnitus (55 patients), and cognitive dysfunction (44 patients). Technical success rate was 100%. Mean post-treatment Bern SIH score was 0.9±1.6 (P<0.0001). Following treatment, 95% of patients reported significant improvement or resolution in symptoms (58 patients reporting resolution and 37 reporting improvement). 5 patients reported no improvement. There were no major procedural or periprocedural complications. 10 patients had minor procedural complications that did not result in any change in management (Onyx emboli, venous perforation). 19 patients had rebound intracranial hypertension requiring acetazolamide therapy. 7 patients had recurrent fistula at the initially treated level. Conclusions Transvenous embolization of CSFVF in SIH patients is safe and effective with a 95% treatment response, significant improvement in imaging outcomes, and a very low rate of complications.
Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy
Coelho, Teresa , Dasgupta, Noel R., Parman, Yeşim , França, Marcondes C. , Guo, Yuh‐Cherng , Wixner, Jonas , Ro, Long‐Sun , Calandra, Cristian , Kowacs, Pedro André , Weiler, Markus , Jung, Shiangtung W., Büchele, Gustavo, Chen, Jersey , Hughes, Steven G. , Schneider, Eugene, Viney, Nicholas J. , Masri, Ahmad , Gertz, Morie R., Ando, Yukio, Khella, Sami, Dyck, P. James B. , Investigators, NEURO-TTRansform, Gane, Edward , Dávila, Lucía Galán, Mezei, Michelle M. , Moreno, Juan González, Cintas, Pascal , Traub, Rebecca , Khoury, Julie, Estol, Conrado J. , Polydefkis, Michael , Brannagan, Thomas H., Rugiero, Marcelo, Distad, B. Jane, Papanicolaou, Eleni Zamba, Lin, Kon‐Ping, Benson, Merrill D., Scheinberg, Morton , Gillmore, Julian D , Marques, Wilson , Chao, Chi‐Chao , Berk, John L. , Obici, Laura , Barroso, Fábio , Conceição, Isabel , Brambatti, Michela , Gertz, Morie A. , Ando, Yukio, Gillmore, Julian D. , Waddington‐Cruz, Márcia , Investigators, NEURO-TTRansform, Mazzeo, Anna Teresa , Papagianni, Aikaterini E. , Dimachkie, Mazen M. , Zaganas, Ioannis V. , Luigetti, Marco , Pareyson, Davide , Needham, Merrilee , Adams, David , Bril, Vera , Attarian, Shahram , Lin, Kon‐Ping

Mayo Clinic

JAMA | September 28, 2023 | Volume: 330 | Issue: 15 | Pages: 1448

10.1001/jama.2023.18688 | PMID 37768671 Get It

Importance Transthyretin gene silencing is an emerging treatment strategy for hereditary transthyretin (ATTRv) amyloidosis. Objective To evaluate eplontersen, an investigational ligand-conjugated antisense oligonucleotide, in ATTRv polyneuropathy. Design, Setting, and Participants NEURO-TTRansform was an open-label, single-group, phase 3 trial conducted at 40 sites across 15 countries (December 2019-April 2023) in 168 adults with Coutinho stage 1 or 2 ATTRv polyneuropathy, Neuropathy Impairment Score 10-130, and a documented TTR variant. Patients treated with placebo from NEURO-TTR ( NCT01737398 ; March 2013–November 2017), an inotersen trial with similar eligibility criteria and end points, served as a historical placebo (“placebo”) group. Interventions Subcutaneous eplontersen (45 mg every 4 weeks; n = 144); a small reference group received subcutaneous inotersen (300 mg weekly; n = 24); subcutaneous placebo weekly (in NEURO-TTR; n = 60). Main Outcomes and Measures Primary efficacy end points at week 65/66 were changes from baseline in serum transthyretin concentration, modified Neuropathy Impairment Score +7 (mNIS+7) composite score (scoring range, –22.3 to 346.3; higher scores indicate poorer function), and Norfolk Quality of Life Questionnaire–Diabetic Neuropathy (Norfolk QoL-DN) total score (scoring range, –4 to 136; higher scores indicate poorer quality of life). Analyses of efficacy end points were based on a mixed-effects model with repeated measures adjusted by propensity score weights. Results Among 144 eplontersen-treated patients (mean age, 53.0 years; 69% male), 136 (94.4%) completed week-66 follow-up; among 60 placebo patients (mean age, 59.5 years; 68% male), 52 (86.7%) completed week-66 follow-up. At week 65, adjusted mean percentage reduction in serum transthyretin was −81.7% with eplontersen and −11.2% with placebo (difference, −70.4% [95% CI, −75.2% to −65.7%]; P &amp;lt; .001). Adjusted mean change from baseline to week 66 was lower (better) with eplontersen vs placebo for mNIS+7 composite score (0.3 vs 25.1; difference, −24.8 [95% CI, −31.0 to −18.6; P &amp;lt; .001) and for Norfolk QoL-DN (−5.5 vs 14.2; difference, −19.7 [95% CI, −25.6 to −13.8]; P &amp;lt; .001). Adverse events by week 66 that led to study drug discontinuation occurred in 6 patients (4%) in the eplontersen group vs 2 (3%) in the placebo group. Through week 66, there were 2 deaths in the eplontersen group consistent with known disease-related sequelae (cardiac arrhythmia; intracerebral hemorrhage); there were no deaths in the placebo group. Conclusions and Relevance In patients with ATTRv polyneuropathy, the eplontersen treatment group demonstrated changes consistent with significantly lowered serum transthyretin concentration, less neuropathy impairment, and better quality of life compared with a historical placebo. Trial Registration ClinicalTrials.gov Identifier: NCT04136184 ; EU Clinical Trials Register: EudraCT 2019-001698-10